02.19.26 -- Could Moving To This Swiss Life Sciences Hub Be In Your Company's Future?

Samir Shah describes how large pharmaceutical companies are moving decisively toward FSP-derived models. He explains how AI investments, cost efficiency, and improved control over operations are driving a lasting structural shift — not a short-term trend — across the industry.

Site-facing technology is presented as a crucial enabler of efficient trial execution, aligning site operations with sponsor timelines and objectives.

Proper planning for first-in-human studies is crucial to successful drug development, which requires innovative trial designs and sound CMC strategies to mitigate risk and expedite proof-of-concept.

For early-stage biotech companies, the road from discovery to market is fraught with challenges, and in this environment, strategic partnerships with CROs have become a cornerstone of clinical success.

PCI Pharma Services' end-to-end injectable services, comprehensive approach, and dedication to excellence provide convenient, easy-to-use, patient-centric therapies.

With three clinical pharmacology units, access to 145,000+ hepatic/renal patients, and 100+ completed studies, we’re your partner for NDA-enabling trials.

The Clinical Trials Regulation and its centralized digital platform, the Clinical Trials Information System (CTIS), are now mandatory. Are you prepared to navigate your next clinical trial in the EU?

Mastering the complexities of multi-regional clinical trials requires aligning global data with evolving regulatory expectations to ensure treatment consistency and successful drug approval.

By fostering a culture of continuous improvement through internal audits, clinical research sites can identify non-compliance issues and enhance their research practices.

Explore how EU GMP Annex 11 revisions could reshape global pharmaceutical compliance, as well as strategies for navigating implementation challenges and building future-ready validation programs.